Chitra Lal1, Gary Hardiman2, Suchit Kumbhare3,4, Charlie Strange3. 1. Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB Suite 816, MSC 630, Charleston, SC, 29425, USA. lalch@musc.edu. 2. MUSC Bioinformatics, Center for Genomics Medicine, Medical University of South Carolina, Charleston, SC, USA. 3. Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB Suite 816, MSC 630, Charleston, SC, 29425, USA. 4. Medical University of South Carolina, Charleston, SC, USA.
Abstract
PURPOSE: There are currently no biomarkers that are associated with cognitive impairment (CI) in patients with obstructive sleep apnea syndrome (OSAS). This pilot study performed an exploratory plasma proteomic analysis to discover potential biomarkers and explore proteomic pathways that differentiate OSAS subjects with and without CI. METHODS: Participants were selected from a cohort of women within 5 years of menopause not on hormone replacement therapy between the ages of 45-60 years. The Berlin questionnaire was used to select OSAS participants who then completed the MCFSI (Mail-In Cognitive Function Screening Instrument) to measure cognition. Six subjects with the highest MCFSI scores (≥ 5 denoting CI) were compared to six with normal scores. Proteomic analysis was done by Myriad RBM using a targeted ELISA for 254 serum proteins. Pathway analysis of differentially expressed proteins was performed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) software. RESULTS: Distinct proteomic signatures were seen in OSAS subjects with CI as compared to those without CI. Proteins including insulin, prostasin, angiopoietin-1, plasminogen activator inhibitor 1, and interleukin-1 beta were overexpressed in OSAS subjects with CI. Proteins underexpressed in CI participants included cathepsin B, ceruloplasmin, and adiponectin. Pathway analysis revealed prominence of insulin-regulated vascular disease biomarkers. CONCLUSIONS: Proteomic biomarkers in participants with cognitive impairment suggest roles for insulin, and vascular signaling pathways, some of which are similar to findings in Alzheimer's disease. A better understanding of the pathogenic mechanisms of CI in OSAS will help focus clinical trials needed in this patient population.
PURPOSE: There are currently no biomarkers that are associated with cognitive impairment (CI) in patients with obstructive sleep apnea syndrome (OSAS). This pilot study performed an exploratory plasma proteomic analysis to discover potential biomarkers and explore proteomic pathways that differentiate OSAS subjects with and without CI. METHODS:Participants were selected from a cohort of women within 5 years of menopause not on hormone replacement therapy between the ages of 45-60 years. The Berlin questionnaire was used to select OSAS participants who then completed the MCFSI (Mail-In Cognitive Function Screening Instrument) to measure cognition. Six subjects with the highest MCFSI scores (≥ 5 denoting CI) were compared to six with normal scores. Proteomic analysis was done by Myriad RBM using a targeted ELISA for 254 serum proteins. Pathway analysis of differentially expressed proteins was performed using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) software. RESULTS: Distinct proteomic signatures were seen in OSAS subjects with CI as compared to those without CI. Proteins including insulin, prostasin, angiopoietin-1, plasminogen activator inhibitor 1, and interleukin-1 beta were overexpressed in OSAS subjects with CI. Proteins underexpressed in CI participants included cathepsin B, ceruloplasmin, and adiponectin. Pathway analysis revealed prominence of insulin-regulated vascular disease biomarkers. CONCLUSIONS: Proteomic biomarkers in participants with cognitive impairment suggest roles for insulin, and vascular signaling pathways, some of which are similar to findings in Alzheimer's disease. A better understanding of the pathogenic mechanisms of CI in OSAS will help focus clinical trials needed in this patient population.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Helena Gylling; Maarit Hallikainen; Jussi Pihlajamäki; Piia Simonen; Johanna Kuusisto; Markku Laakso; Tatu A Miettinen Journal: J Lipid Res Date: 2010-05-01 Impact factor: 5.922
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: Stuart F Quan; Cynthia S Chan; William C Dement; Alan Gevins; James L Goodwin; Daniel J Gottlieb; Sylvan Green; Christian Guilleminault; Max Hirshkowitz; Pamela R Hyde; Gary G Kay; Eileen B Leary; Deborah A Nichols; Paula K Schweitzer; Richard D Simon; James K Walsh; Clete A Kushida Journal: Sleep Date: 2011-03-01 Impact factor: 5.849
Authors: Leonardo Nimrichter; Monica M Burdick; Kazuhiro Aoki; Wouter Laroy; Mark A Fierro; Sherry A Hudson; Christopher E Von Seggern; Robert J Cotter; Bruce S Bochner; Michael Tiemeyer; Konstantinos Konstantopoulos; Ronald L Schnaar Journal: Blood Date: 2008-06-25 Impact factor: 22.113
Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki Journal: Nat Med Date: 2001-08 Impact factor: 53.440
Authors: Ina Djonlagic; Mengshuang Guo; Paul Matteis; Andrea Carusona; Robert Stickgold; Atul Malhotra Journal: PLoS One Date: 2014-01-29 Impact factor: 3.240
Authors: Takeshi Fujisawa; Keqing Wang; Xi-Lin Niu; Stuart Egginton; Shakil Ahmad; Peter Hewett; Christopher D Kontos; Asif Ahmed Journal: Cardiovasc Res Date: 2017-01 Impact factor: 10.787
Authors: Julian M Gaitán; Hyo Youl Moon; Matthew Stremlau; Dena B Dubal; Dane B Cook; Ozioma C Okonkwo; Henriette van Praag Journal: Front Endocrinol (Lausanne) Date: 2021-05-20 Impact factor: 5.555